Home

Welcome to ECTRIMS

The European Committee for Treatment and Research in Multiple Sclerosis is a non-profit, independent, representative European-wide organisation that serves as Europe’s and the world’s largest professional organisation dedicated to the understanding and treatment of multiple sclerosis.

Discover your ECTRIMS Fellowship

Our three ECTRIMS fellowships in Clinical Training, Postdoctoral Research, and Nurse & AHP Training are dedicated to helping young MS professionals advance their knowledge & expertise in the field of MS.

> Read more

CALL for Nominations

The International Advisory Committee on Clinical Trials in MS is seeking nominations for new members to join the committee for the term commencing in January 2023.

> Read more

E-Insights: MS and Cognition

How does MS affect cognition, and what are the underlying factors? The latest ECTRIMS insights explores the multifaceted factors affecting cognitive impairment, from physical impairment to education levels.

> Read More

Apply for a 2023 ECTRIMS Fellowship

Experience the Evolution: Register for ECTRIMS 2022

Digitally United - Wrapping up ECTRIMS 2021

EAN/ECTRIMS Vaccination Standards for MS patients

ECTRIMS 2021:
Be part of an outstanding digital experience 13-15 October 2021

ECTRIMS Focused Workshop 2021 - Highlights

Stay connected

Find below our Twitter-Feed to get the hottest news.

ECTRIMS @ECTRIMS·

22h

Did you know that #ECTRIMS2022 is also offering Education Sessions, designed to provide ... you with key learnings into today’s most pressing #MS topics, from #COVID19 to the treatment of #ProgressiveMS.

Learn more about how to register for them here ▶️ https://bit.ly/3tOywCn

ECTRIMS @ECTRIMS·

17 Aug

📣 Discover how our three ECTRIMS 2023 fellowships - in #ClinicalTraining, ... #PostdoctoralResearch and #Nurse & #AHP Training - can help advance your knowledge & expertise in the field of #MS

➡️ https://www.ectrims.eu/fellowships/

ECTRIMS @ECTRIMS·

15 Aug

#MSJournal: Newly published research by @MonashUni, @SWSLHD, @Uni_Newcastle et. al. ... discusses prediction of relapse activity when switching to #Cladribine for #MS. Switching from #Natalizumab is also independently associated with greater relapse hazard: https://bit.ly/3T1MxHQ

ECTRIMS @ECTRIMS·

12 Aug

#MSJournal: Researchers from @karolinskainst & @orebrouni conclude metabolic surgery ... to be safe for #obesepatients w/ #MS, but the course of MS might be negatively affected. Nutritional follow-up post surgery & supplementation maintenance are crucial

➡️ https://bit.ly/3p1ZxPL

ECTRIMS @ECTRIMS·

11 Aug

CALL for nominations: The International Advisory Committee on Clinical Trials in MS is ... seeking nominations for new members to join the committee for the term commencing in January 2023. The nomination deadline is 30 Sep @mssociety

Learn more here: https://bit.ly/3zLtgS3

ECTRIMS @ECTRIMS·

10 Aug

#MSJournal: @Lauz_Caccia and @rocca_mara from @NRU_SanRaffaele find that TVC rather than ... SFC of the precuneus correlates with NMOSD neuropsychological features; different TVC abnormalities underlie depressive symptoms and cognitive impairment.

➡️ https://bit.ly/3Qd9JRt

Click here to > Load More

Discover your ECTRIMS Fellowship

CALL for Nominations

E-Insights: MS and Cognition

Apply for a 2023 ECTRIMS Fellowship

Experience the Evolution: Register for ECTRIMS 2022

Digitally United - Wrapping up ECTRIMS 2021

EAN/ECTRIMS Vaccination Standards for MS patients

ECTRIMS 2021:Be part of an outstanding digital experience 13-15 October 2021

ECTRIMS Focused Workshop 2021 - Highlights

Stay connected

ECTRIMS 2021:
Be part of an outstanding digital experience 13-15 October 2021